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Abstract: Suboptimal vitamin D status is associated with elevated blood pressure (BP) in children
and adolescents. Whether vitamin D supplementation reduces BP remains unclear. To systematically
review whether vitamin D supplementation reduces BP in children and adolescents, we conducted
a literature review according to the PRISMA statement. We included vitamin-D supplementation
human interventions studies that reported on BP as an outcome. We searched PUBMED, MEDLINE,
CINAHL, EMBASE, the Cochrane Library, and the clinical trials website. We also hand searched
the references of the included articles and previous reviews of vitamin D therapy. No language or
time restrictions were applied. We extracted data on population characteristics, baseline and endline
vitamin D and BP values, and assessed the risk of bias of the included studies. We performed a
narrative review of the findings, conducted a meta-analysis when possible, and performed sensitivity
analyses to test the robustness of our results. We assessed the overall quality of the evidence
produced in the meta-analysis. We included eight studies in our review and five studies in the
meta-analysis, none of which included hypertensive only participants. The risk of bias was variable.
In non-randomized studies, no effect of vitamin D supplementation was seen on systolic BP (SBP)
(mean difference: 0.39 (95% confidence interval (CI): −0.9; 1.68) mmHg; p = 0.55; I2 = 0%). Only a
significant decrease in diastolic BP (DBP) (mean difference: −1.87 (95% CI: −3.02; −0.72) mmHg;
p = 0.001; I2 = 0%) was noted. Both analyses had a low quality of evidence. In randomized controlled
trials (RCTs), no effect was noted on SBP (mean difference: −2.04 (95% CI: −5.12; 1.04) mmHg;
p = 0.19; I2 = 71%) nor DBP (mean difference: 0.01 (95% CI: −1.09; 1.12) mmHg; p = 0.98; I2 = 0%).
The final quality of evidence ranged between low and moderate. Sensitivity analyses did not affect
the results. Vitamin D supplementation was found to be ineffective in lowering SBP and DBP in
children and adolescents.
Keywords: vitamin D; blood pressure; children; adolescents; systematic review; meta-analysis

1. Introduction
Vitamin D, recently coined as the D hormone, is a pleiotropic steroid hormone that has multiple
biological effects. Most notably, it plays an integral function in the regulation of calcium and phosphorus
homeostasis, and thus has a vital role in bone health. Emerging evidence suggests further extra-skeletal
physiological actions, but clinical consequences are still debatable [1–4].
Hypovitaminosis D, or low serum levels of 25-hydroxyvitamin D (25OHD), is widespread in both
adults and children around the world [5,6]. The most common determinants of deficiency include
limited sunlight exposure, diseases that cause malabsorption (i.e., celiac disease, cystic fibrosis), diet,
obesity, and altered metabolism secondary to some medications [4,7].
Hypertension, or elevated blood pressure (BP), is a well-recognized risk factor for both
cardiovascular and renal diseases in addition to a vast array of diseases contributing significantly to
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mortality [8,9]. Specifically, childhood hypertension poses a considerable public health challenge [10],
and is associated with essential hypertension in adults and detrimental cardiovascular events [9,11].
Recent pooled estimates suggest the global prevalence of childhood hypertension has reached 4%, and
that it is generally more common in adolescents undergoing puberty and children who are overweight
or obese. Furthermore, an upward trend in childhood hypertension has been observed during the past
two decades, with a relative rate increase of 75% to 79% from 2000 to 2015. This increase in prevalence
is expected to persist in the future [10].
Among adults, a wealth of observational data has demonstrated a relationship between low serum
levels of 25OHD and hypertension [12–14], although no evidence of a clinically significant reduction in
BP as a result of vitamin D supplementation has been observed [14].
Among children and adolescents, Dolinsky et al. systematically reviewed the association between
vitamin D and BP [15]. The majority of included observational studies found an inverse association
between 25OHD and systolic blood pressure (SBP) [14]. Likewise, obese children with low levels
of vitamin D showed increased odds for hypertension, even after adjusting for body mass index
and body fat [16]. Such observations are supported by biologically plausible mechanisms that could
mediate an effect of vitamin D on BP, such as the presence of vitamin D receptors on endothelial
cells, smooth muscle cells, and myocytes [17], or the beneficial effect of vitamin D in improving
endothelial function, reducing the production of proinflammatory cytokines, regulating the activity of
the renin–angiotensin–aldosterone system and preventing secondary hyperparathyroidism [14,18–20].
Nevertheless, human interventions studies have produced conflicting evidence on the antihypertensive
effect of supplementation with vitamin D, where no change in SBP or diastolic blood pressure (DBP)
was recorded even when 25OHD increased upon supplementation [21]. The fact that it is unlikely that
vitamin D supplements are beneficial for improving bone density in healthy children and adolescents led
us to conduct this study and explore the effect of these supplements on BP in children and adolescents.
Preventing vitamin D deficiency or correcting it through supplementation could be of public
health relevance, especially since it is an inexpensive intervention already used in children and
adolescents to improve bone health. This study aims to systematically review the literature on the
relationship between vitamin D supplementation and BP in children and adolescents, and meta-analyze
available data.
2. Methods
2.1. Review Design
The review was conducted according to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement. We conducted the systematic review following a predefined
protocol that was submitted to the International Prospective Register of Systematic Reviews
(PROSPERO). Ethical approval was not required for the current study. We included human interventions
studies that reported on BP (systolic or diastolic) as an outcome, and supplementation with vitamin
D. We also included observational studies that reported BP (systolic or diastolic) as an outcome, and
vitamin D deficiency as an exposure. We searched the following databases: PUBMED, MEDLINE,
CINAHL, EMBASE, the Cochrane Library, and the clinical trials website [22].
We also hand searched the references of the included articles and previous reviews of vitamin
D status and therapy in children and adolescents as identified by the search. No language or time
restrictions were applied to eligible reports. For this review, only studies reporting on vitamin D
supplementation and BP were considered.
2.2. Search Strategy
We considered three key concepts: (1) vitamin D, (2) blood pressure, and (3) children
and adolescents. For each of the three concepts, we mapped Medical Subject Headings (MeSH)
and keywords. Search terms included but were not limited to: vitamin D, cholecalciferol,
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ergocalciferol or calcidol, combined with blood pressure or hypertension, and pediatric, child,
adolescent, youth or teenage. The search period spanned 1 January 1966, through 17 January 2020.
The electronic search strategy was validated by a medical information specialist and is described in the
Supplementary Materials.
2.3. Study Selection
We considered cross-sectional, case-control, retrospective, or prospective cohort studies;
and randomized, non-randomized, controlled, or uncontrolled clinical trials including children
and adolescents as defined by the studies (e.g., aged less than 18 years). For this review, we included
studies evaluating the effect of vitamin D supplementation on BP reduction. We specifically considered
interventions such as vitamin D3 (cholecalciferol) or other forms of supplementation, including vitamin
D-fortified milk with a duration of at least 4 weeks to ensure that the intervention had sufficient time to
produce an effect. The main outcome for controlled trials was the difference in measured BP (SBP, DBP
or mean arterial pressure) readings between control and intervention groups, and the main outcome
for non-controlled trials was the change in measured BP readings from baseline through follow-up.
Studies solely including adult patients as defined by the studies (e.g., aged 18 years and above),
studies conducted on pregnant women, cord blood, neonates and infants, studies focused on participants
with diseases (e.g., inborn errors of metabolism, cancer, transplant, seizures, chronic kidney disease,
dialysis, liver disease, parathyroid abnormality, and vitamin D-dependent rickets types 1 and 2),
studies focused on participants taking medications known to interfere with vitamin D metabolism
(e.g., phenytoin, phenobarbital, carbamazepine, and rifampin), and studies evaluating the association
between hypovitaminosis (deficiency or insufficiency of vitamin D status) or hypervitaminosis D and
BP were excluded.
The author screened titles and/or abstracts retrieved by the search and identified studies that
potentially met the inclusion criteria outlined above. The full texts of potentially eligible studies were
retrieved and assessed for eligibility.
2.4. Data Extraction
The author extracted data from eligible studies using a data extraction form. For all eligible records,
the author recorded the characteristics of the study, details of the population included, the intervention
applied and its comparator, as well the main findings and adjustments to the analyses, where applicable.
Serum 25OHD was converted to nanomoles per liter (nmol/L) if it was reported as nanograms per
milliliter (ng/mL) by multiplying by a factor of 2.496.
2.5. Risk of Bias Assessment
The author assessed each included study for risk for bias. For randomized controlled trials,
the Cochrane criteria [23] (sequence generation, allocation concealment, blinding of participants
and outcome assessors, incomplete outcome data, and selective outcome reporting) were used.
For non-randomized studies, a modified version of the Cochrane Risk of Bias tool [24] (eligibility
criteria, measurement of exposure and outcome, control confounding, and follow-up) was used. Each
potential source of bias was graded as low, high, or unclear risk.
The overall quality of the evidence produced in the meta-analysis was evaluated according to the
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria (high risk
of bias, imprecision, indirectness, heterogeneity, and publication bias) with the use of GRADEpro tool
(Evidence Prime Inc., McMaster University, Hamilton, ON, Canada).
2.6. Data Synthesis
Using RevMan version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre),
we performed standard meta-analysis comparing vitamin D supplementation with no supplementation
according to a random-effects model. We reported on the results of the meta-analysis as the weighted
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mean difference with 95% confidence intervals. Meta-analysis was performed when participants,
treatments and the outcomes were similar enough to allow pooling. When the trial consisted of
two groups, we pooled the two arms of interventions using the formula for combining two arms from
the Cochrane handbook (chapter 16.5.4, table 7.7.a.) [23]. When a meta-analysis was not possible,
we performed a narrative review of the findings. We used the I2 statistic to assess heterogeneity
among different studies in each comparison. In cases of moderate to substantial heterogeneity, with I2
values greater than 50%, we explored and reported on the potential causes. Also, we conducted
sensitivity analyses in regard to having or not having vitamin D deficiency as the inclusion criterion.
The sensitivity analyses were conducted to test the robustness of our results.
3. Results
3.1. Search Results
Details of the search process are presented in Figure 1. We included eight studies in the
systematic review, of which five studies yielded data that could be combined in the meta-analysis.
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Table 1. Characteristics of non-randomized human interventions studies.
Author, Year

Study Design

Geographic
Setting

Ashraf, 2011 [25]

Before/after
study

Birmingham,
USA

Javed, 2015 [26]

Before/after
study

Khayyatzadeh, 2018
[27]

Before/after
study

Rochester, USA

Mashhad and
Sabzevar, Iran

Study Population

Age (Years) and Gender

Intervention

Duration

Daily Dose
Equivalent

Compliance

14 obese post-menarchal female adolescents
(13 African American, 1 Caucasian
American), with serum 25OHD < 75 nmol/L
Mean BMI (SD) in kg/m2 : NR
19 obese adolescents (89.5% non-Hispanic
white), non-hypertensive, with serum
25OHD < 75 nmol/L
Mean BMI (SD) in kg/m2 : deficient: 21.2
(4.4); insufficient: 20.6 (3.6)

Mean (SD)
Pre-treatment: 14.9 (1.8)
Post-treatment: 15.6 (1.7)
% Male: 0%

Vitamin D2
(ergocalciferol, orally,
50,000 IU), once per week

8 weeks

7142.8 IU

NR

Vitamin D3
(cholecalciferol, 2 pills,
50,000 IU each; Total:
100,000 IU), once per
month

12 weeks

3278.7 IU

100%

Vitamin D3
(cholecalciferol, 1 capsule,
50,000 IU), once per week

9 weeks

7142.8 IU

NR
dropout rate:
4.8%

940 healthy female adolescents, not taking
medications or vitamin D supplements
Mean BMI (SD) in kg/m2 : 21.07 (4.2)

Range: 13–18
Mean (SD): 15.8 (1.7)
% Male: NR
Range: 12–18
Deficient: 14.5 (1.53)
Insufficient: 14.7 (1.51)
Sufficient: 15.2 (1.53)
% Male: 0%

25OHD: 25-hydroxyvitamin D; BMI: body mass index; SD: standard deviation; NR: not reported; IU: international units.
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Table 2. Characteristics of RCTs.
Author, Year

Al Daghri,
2019 [28]

Dong, 2010
[29]

Hauger, 2018
[21]

Kelishadi,
2014 [30]

Smith, 2018
[31]

Study Design

Cluster RCT

Open-label,
investigator-blinded
RCT

Double blind,
placebo controlled
RCT

Triple blind,
placebo controlled
RCT

Double blind,
placebo controlled
RCT

Geographic
Setting

Riyadh, Saudi
Arabia

Richmond,
USA

Copenhagen,
Denmark

Isfahan, Iran

United
Kingdom

Study Population
535 healthy children and
adolescents with 25OHD < 50
nmol/L, non-hypertensive, not
taking medications or vitamin
supplements
Mean BMI (SD) in kg/m2 : Total:
23.0 (6.2); Tablet: 23.0 (6.2); Milk:
23.7 (5.6); C: 24.3 (6.4)
44 healthy black (African
American) adolescents,
non-hypertensive, not taking
medications or vitamin
supplements
Mean (SD) BMI percentile:
I: 67.8 (30.9); C: 61.6 (33.4)
(p = 0.53)

Age (Years) and Gender

Intervention

Range: 12-18
Mean (SD): Total: 14.9 (1.9)
Tablet: 14.3 (1.6)
Milk: 14.4 (1.5)
C: 16.1 (1.9)

Tablet: n = 166; vitamin
D tablet, 1000 IU daily

% Male: 45.4%

Range: 14–18
Mean (SD): Total: 16.3 (1.4)
I: 16.5 (1.4)C: 16.3 (1.1)
(p = 0.95)

Duration

Daily Dose
Equivalent

Control

Compliance

24 weeks

Tablet: 1000
IU
Milk: 80 IU

n = 180; no
intervention

Tablet: 91.1%Milk:
90.4%
C: 86.7%

16 weeks

2000 IU

n = 24; vitamin
D3
(cholecalciferol);
400 IU/day

I: 85%
C: 88% (p = 0.65)

20 weeks

I1: 400 IU
I2: 800 IU

n = 43;
placebo-matching
tablet (0 µg
D3/day)

I1: 97.6%
I2: 97.6%

12 weeks

42,857 IU

n = 22;
placebo-matching
capsule

I: 88%
C: 96% from
original sample

20 weeks

I1: 400 IU
I2: 800 IU

Milk: n = 189; 200 mL
of vitamin D-fortified
milk, 40 IU/100 mL,
daily

n = 25; vitamin D3
(cholecalciferol), 2000
IU/day

% Male: 55.5%

119 healthy white children of
European origin, not taking
vitamin D supplement for ≥1
month prior to the study and not
planning a winter sun vacation
Normal weight: I1: 90%; I2: 92%;
C: 66%
43 children and adolescents with
metabolic syndrome and BMI ≥3
Z-scores, not taking medication
or supplementation use, free of
other chronic disease
Mean BMI (SD) in kg/m2 :
C: 27.81(1.04); I: 28.08 (1.06)

Range: 4–8
Mean (SD): Total: 6.7 (1.5)
I1: 6.9 (1.5)
I2: 6.7 (1.4)
C: 6.5 (1.5)

102 healthy white adolescents,
not taking vitamin D
supplement or planning a winter
sun vacation
Normal weight: I1: 80%; I2: 84%;
C: 79%

Range: 14–18
Mean (SD): 15.9 (1.4)
I1: 16.0 (1.4)
I2: 15.9 (1.5)
C: 15.9 (1.4)
% Male: 43%

% Male: 36%

Range 10–16

I1: n = 44; 10 µg D3
tablet/day
I2: n = 43; 20 µg D3
tablet/day

n = 21; 300,000 IU
vitamin D3, 1
capsule/week

% Male: NR

I1: n = 39; 10 µg D3
tablet/day
I2: n = 36; 20 µg D3
tablet/day

C: n = 43;
placebomatching Tablet
(0 µg D3/day)

I1: 94.2%
I2: 94.4%

RCT: randomized controlled trial; 25OHD: 25-hydroxyvitamin D; BMI: body mass index; SD: standard deviation; C: control; IU: international units; I: intervention; NR: not reported.
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The articles included three non-randomized human interventions studies [25–27] and five
controlled trials of vitamin D supplementation [28–31]. Three of the studies were conducted in the
USA [25,26,29], two in Iran [27,30], one in Denmark [32], and one in each of Saudi Arabia [28] and
the United Kingdom [31]. Participant age in the studies ranged from 4 to 18 years, and participant
sample size ranged from 14 to 940. Two of the non-randomized trials [25,26] were conducted on obese
adolescents, and two of them [25,27] included females exclusively. As for the RCTs, all of them were
conducted on reportedly healthy individuals, except in Kelishadi et al. [30] which included participants
with obesity and metabolic syndrome. In this study [30], the authors adopted a continuous value
of metabolic syndrome, which was calculated as the sum of the standardized residuals (Z-scores)
of the individual variables of waist circumference, high density lipoprotein cholesterol (multiplied
by −1), triglycerides, fasting blood glucose, and mean arterial blood pressure based on age and
gender, and whereby a higher continuous value of metabolic syndrome score indicated a less favorable
metabolic profile. This score is validated in Iranian children and adolescents.
None of the studies, whether randomized or not, included only hypertensive participants. Further,
in Khayyatzadeh et al. [27], Javed et al. [26], Dong et al. [29], Al Daghri et al. [28], Hauger et al. [32] and
Smith et al. [31], only healthy, non-hypertensive subjects were recruited. No details regarding baseline
prevalence of hypertension were provided in Ashraf et al. [25]. Finally, although Kelishadi et al. [30]
included participants with metabolic syndrome, the prevalence of elevated BP at baseline was
not reported. All of the studies assessed changes in SBP and DBP, except Al Daghri et al. [27], who
also assessed the prevalence of elevated BP (defined as ≥90th percentile for age, sex and height), and
Kelishadi et al. [30], who solely assessed mean arterial pressure.
Regarding vitamin D status, two out of the three non-randomized human interventions studies
were conducted on participants with either vitamin D deficiency [25] or insufficiency [26]. Inadequate
vitamin D status was not an inclusion criterion only the study by Khayyatzadeh et al. [27], although
around 95% of the study population were either vitamin D deficient or insufficient. In four [28–31] out
of the five included RCTs, mean baseline vitamin D was less than 50 nmol/L.
In the non-randomized human interventions studies, the interventions varied between oral
vitamin D2 [25] or D3 supplementation [26,27]. The daily equivalent dose ranged from 3279 IU [26]
to 7143 IU [25,27], and the intervention period ranged from eight weeks [25] to three months [26].
In all included RCTs, the interventions consisted of vitamin D3 supplementation, except in the study
by Al Daghri et al. [28], which also included another treatment arm consisting of supplementation
through vitamin D-fortified milk. The duration of supplementation ranged from 12 weeks [29] to six
months [28], with a daily equivalent dose ranging from 80 IU [28] to 42,857 IU [30].
3.3. Results of Included Studies
Tables 3 and 4 describe the findings from the included studies.
All non-randomized human intervention studies reported a significant increase in 25OHD after
supplementation. No significant association was reported between 25OHD and either SBP or DBP in
Ashraf et al. [25] and Javed et al. [26]. Only Khayyatzadehet al. [27] reported an overall significant
reduction in DBP (SD) from 62.3 (13.4) to 60.0 (12.9) mmHg, which was also noted in all of the deficient,
insufficient and sufficient at baseline subcategories.
As for the RCTs, none of the studies reported significant changes in either SBP or DBP over time, in
intra- or inter-group comparisons, except Al Daghri et al. [28]. In this study, a significant change in BP
was noted; the authors reported a significant decrease in SBP over time in all the study groups, including
the control group, with a significant inter-group difference in favor of the vitamin D tablet group.
Also, Al Daghri et al. reported a significant decrease in DBP over time in both the vitamin D tablet
and control groups [28]. This was a significant inter-group difference in favor of the control group.
Similarly, the prevalence of elevated BP decreased significantly in the vitamin D tablet and control
groups, from 38.9% to 25%, and from 34.9% to 24.7%, respectively.
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Table 3. Results of non-randomized human intervention studies.
Author, Year

Outcomes Evaluated

Mean (SD) Baseline 25OHD
(nmol/L)

Mean (SD) Endline 25OHD
(nmol/L)

Mean (SD) Baseline BP
(mmHg)

Mean (SD) Endline BP (mmHg)

Conclusion

Ashraf, 2011 [25]

Serum 25OHD: liquid
chromatography-tandem mass
spectrometry
SBP and DBP: automated
blood pressure cuff appropriate
for arm size (number of
measurements: NR)

26.4 (10.9)

63.6 (30.2)
(p < 0.001)

SBP: 123 (14)
DBP: 65 (9)

SBP: 118 (15) (p: 0.41)
DBP: 64 (8) (p: 0.72)

NS change in SBP and
DBP

Javed, 2015 [26]

Serum 25OHD: liquid
chromatography-tandem mass
spectrometry
SBP and DBP: average of 2
measures by aneroid
sphygmomanometer with the
participant’s arm supported
and positioned at the level of
the heart taken after >10
minute rest

55.9 (12.2)

86.9 (16.7) (p < 0.001)

NR

NR

NS change in SBP and
DBP

SBP:
Total: 96.8 (14.5) (p = 0.63 in
adjusted model)
Deficient: 97.1 (14.6) (p = 0.48)
Insufficient: 98.2 (13.1) (p = 0.77)
Sufficient: 95.6 (14.2) (p = 0.05)
DBP: Total: 60.0 (12.9) (p = 0.03 in
adjusted model)
Deficient: 60.7 (13.01) (p = 0.005)
Insufficient: 60.9 (10.5) (p < 0.001)
Sufficient: 61.9 (12.7) (p = 0.002)

Significant reduction
in DBP and NS
change in SBP

Serum 25OHD:
electrochemi-luminescence
Khayyatzadeh, 2018
[27]
SBP and DBP: standard
procedure (procedure not
detailed)

Total: 23.6 (22.04)
Deficient: 17.2 (9.4)
Insufficient: 60.07 (8.1)
Sufficient: 99.5 (22.2)

Total: 90.9 (38.6) (p < 0.001)
Deficient: 89.1 (37.7) (p < 0.001)
Insufficient: 99.9 (46.9) (p < 0.001)
Sufficient: 116.1 (36.6) (p < 0.001)

SBP:
Total: 96.4 (14.2)
Deficient: 96.6 (14.2)
Insufficient: 98.3 (14.3)
Sufficient: 98.8 (11.2)
DBP:
Total: 62.3 (13.4)
Deficient: 62.5 (13.05)
Insufficient: 64.5 (12.8)
Sufficient: 66.05 (10.4)

SD: standard deviation; BP: blood pressure; 25OHD: 25-hydroxyvitamin D; SBP: systolic blood pressure; DBP: diastolic blood pressure; NS: not significant; NR: not reported; IU:
international units.
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Table 4. Results of RCTs.
Author, Year

Outcomes Evaluated

Mean (SD) Baseline
25OHD (nmol/L)

25OHD: enzyme linked immunosorbent
assay

Al Daghri, 2019 [28]
SBP and DBP: average of 2 measures by
a conventional mercurial
sphygmomanometer taken after a
30-minute rest

Tablet: 30.8 (9.3)
Milk: 31.8 (8.1)
C: 29.8 (10.3) (p = 0.46)

Mean (SD) Endline
25OHD (nmol/L)

Tablet: 41.5 (14.4)
Milk: 38.1 (11.9)
C: 31.9 (13.8) (p < 0.001)
(p = 0.73 between tablet
and milk; <0.001 between
tablet and C; p < 0.001
between milk and control)

Serum 25OHD: liquid
chromatography-tandem
mass spectrometry

SBPI: 111.3 (10.4)
C: 114.9 (7.8) (p = 0.20)
DBP
I:68.2 (12.3)
C: 69.4 (6.5) (p = 0.17)

NR

I1: 56.9 (12.7)
I2: 58.1 (13.5)
C: 55.2 (10.8)

I1: 61.8 (10.6)
I2: 75.8 (11.5)
C: 31.1 (7.5) (p < 0.001)

SBP:
I1: 95.7 (4.6)
I2: 96.4 (4.4)
C: 97.1 (5.5)

SBP:
I1: 95.6 (4.4)
I2: 96.9 (4.4)
C: 96.6 (4.2) (NS)

DBP:
I1: 58.8 (4.1)
I2: 59.9 (4.6)
C: 59.2 (4.1)

DBP:
I1: 58.5 (4.5)
I2: 60.5 (3.8)
C: 59.9 (3.3) (NS)

SBP and DBP: average of 2 out of 3
readings, 10 minutes apart, by an
automated monitor in a supine position

Kelishadi, 2014 [30]

Serum 25OHD: liquid
chromatography-tandem mass
spectrometry
Smith, 2018 [31]

SBP and DBP: average of 3 readings, 1
min apart, by an automated BP monitor
on the non-dominant arm in an upright
position with the arm supported

SBP:
Tablet: 112.3 (12.3)
Milk: 115.3 (16.1)
C: 117.1 (14.9) (p = 0.005) (p = 0.44
between tablet and milk; p = 0.004
between tablet and C; p = 0.19
between milk and C)
DBP:
Tablet: 69 (11.4)
Milk: 75.6 (15.7)
C: 68.1 (11.1) (p < 0.001)
(p < 0.001 between tablet and milk; p
= 0.94 between tablet and C; p <
0.001 between milk and C)
Elevated BP:
Tablet: 25.0% (p < 0.001)
Milk: 44.4% (NS)
C: 24.7% (p < 0.05)

I: 85.7 (30.1)
C: 59.8 (18.2) (p < 0.001)

Hauger, 2018 [32]

Serum 25OHD: chemiluminescent
immunoassay method
Mean arterial pressure: ((SBP − DBP)/3)
+ DBP; with SBP and DBP measured
using standard protocol with calibrated
instruments (procedure not detailed)

DBP:
Tablet: 71.9 (11.9)
Milk: 73.3 (15.7)
C: 72.5 (11.6) (p = 0.50)

Mean (SD) Endline BP (mmHg)

I: 33.1 (8.7)
C: 34.0 (10.6) (p = 0.76)

Plasma 25OHD: enzyme immunoassay
SBP and DBP: average of 3 measures, 2
minutes apart, by a vital signs monitor
after a 5-minute rest

SBP:
Tablet: 117.3 (14.4)
Milk: 117.9 (14.4)
C: 120.9 (14.9) (p = 0.75)

Elevated BP:
Tablet: 38.9%
Milk: 40.7%
C: 34.9%

Elevated BP: ≥90th percentile for age,
sex and height

Dong, 2010 [29]

Mean (SD) Baseline BP
(mmHg)

Conclusion

Significant decrease in SBP in
all groups. Between-group
significant decrease in favor of
the tablet group (p = 0.005)

Significant decrease in DBP in
the tablet and control groups.
Between-group significant
improvement in favor of
control (p < 0.001)
Significant reduction in
elevated BP in the tablet and
control groups (p < 0.05)
NS change in SBP or DBP over
time in the control or
intervention groups (p > 0.05)
NS change in SBP or DBP
when adjusted for baseline
value of the outcome
Marginally higher DBP of 1.4
mmHg (95% CI: −0.0,2.8; p =
0.05) in I1 compared with I2
Marginally lower DBP of
−1.2mmHg (95% CI: −2.7, −0.0;
p = 0.05) in I1 compared with C,
which was not observed with I2

I: 45.60 (5.09)
C: 44.7 (5.66) (p = 0.48)

I: 79.89 (5.34)
C: 47.59 (5.01) (p = 0.02)

I: 134.01 (5.89)
C: 136.61 (6.08) (p = 0.53)

I: 131.47 (4.69)
C: 135.26 (4.52) (p = 0.07)

NS change in mean arterial
pressure in intra-group and
inter-group comparisons

I1: 49.2 (12)
I2: 51.7 (13.4)
C: 46.9 (11.4)

I1: 56.6 (12.4)
I2: 63.9 (10.6)
C: 30.7 (8.6) (p < 0.001 for
all groups, from baseline to
endline)

SBP:
I1: 124 (13)
I2:122 (10)
C: 121 (10)
DBP:
I1: 69 (10)
I2: 67 (7)
C: 67 (8)

SBP:
I1: 123 (11)
I2: 121 (8)
C: 123 (14) (NS)
DBP:
I1: 71 (11)
I2: 67 (6)
C: 68 (10) (NS)

NS change in SBP or DBP

SD: standard deviation; 25OHD: 25-hydroxyvitamin D; BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; C: control; I: intervention; NR: not reported; NS:
not significant.

in BP was noted; the authors reported a significant decrease in SBP over time in all the study groups,
including the control group, with a significant inter-group difference in favor of the vitamin D tablet
group. Also, Al Daghri et al. reported a significant decrease in DBP over time in both the vitamin D
tablet and control groups [28]. This was a significant inter-group difference in favor of the control
group. 2020,
Similarly,
and
Nutrients
12, 1163the prevalence of elevated BP decreased significantly in the vitamin D tablet
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control groups, from 38.9% to 25%, and from 34.9% to 24.7%, respectively.
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Dong et al., endline BP values were not presented [21].
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Results from the randomized studies showed no significant effect on SBP nor DBP in normotensive
participants, despite correcting deficient or insufficient vitamin D baseline levels. These findings are in
line with the most recent meta-analysis in children and adolescents, which failed to find any effect
of vitamin D supplementation on SBP and DBP [33]. Also, this is in line with results of previous
systematic reviews and meta-analyses of trials among non-hypertensive adults [34–36]. While some
evidence exists to underpin the modest BP-lowering effect of vitamin D in adult patients who are either
hypertensive [37] or with pre-existing cardiometabolic disease [38], this remains unclear [34], and we
could not ascertain this issue since none of the studies included solely hypertensive patients or those
suffering from cardiometabolic disease.
The optimum serum 25OHD levels in children and adolescents associated with both
skeletal and extraskeletal health outcomes, and the supplementation doses required to achieve it,
remain debatable [2]. Current recommended vitamin D supplementation doses for children and
adolescents vary mainly between 400 and 600 IU/day [39–43], and all of the included studies,
except Hauger et al. [31] and Smith et al. [31] in one of their intervention arms, employed doses
exceeding this range. Further, all of the non-randomized human intervention studies provided doses
exceeding the 2011 Institute of Medicine (IOM) [39] tolerable upper limits (UL) of daily vitamin
D supplementation (2500 IU/d in children aged four to eight years and 3000 IU in older children
and adolescents). Yet, all of these studies did not find a beneficial effect, even when doses doubled
the UL, such as in Ashraf et al. [25] and Khayyatzadeh et al. [27], or when a weekly mega-dose of
300,000 IU (greatly exceeding the IOM UL) was administered, as in Kelishadi et al. [30]. Given the risk
of hypercalcemia, and in light of the absence of any significant BP decrease as found by our study and
elsewhere [33], extremely cautious provision of vitamin D doses exceeding the UL in children and
adolescents should be exercised.
Existing observational data [15] suggest an inverse association between low vitamin D status
and cardiometabolic health, including SBP. Thus, correcting suboptimal vitamin D status was
suggested as a means to improve BP. Our analysis does not support this suggestion. Two of the
non-randomized studies [25,27] included vitamin D-insufficient participants (baseline 25OHD levels
below the recommended IOM level of 50 nmol/L) and both studies reported a non-significant change in
BP. Similarly, in the randomized studies by Hauger et al. [33] and Smith et al. [31] including healthy and
predominantly normal-weighted children and adolescents, despite a significant improvement in serum
25OHD levels in the intervention groups paralleled with a significant decline in the placebo group,
BP remained unchanged across all groups. This is consistent with results noted among adults [44].
This also indicated that the seasonal fluctuation in vitamin D concentration may not compromise
BP in normal-weighted individuals. It also raises the question on the feasibility of winter vitamin D
supplementation on cardiometabolic health in this group. This insignificant change in BP was also
recently reported by Abboud et al. [45], showing no effect of vitamin D status at baseline or of vitamin
D supplementation on changes in SBP or DBP.
On the other hand, the results presented by Al Daghri et al. [28] were interesting. They showed
that in patients with components of metabolic syndrome, a correction of baseline insufficient 25OHD
levels (resulting in significantly higher levels than the control group) exhibited a significant decrease in
SBP and DBP, as well as the prevalence of elevated BP. This could suggest a potential role of vitamin D
supplementation in lowering cardiometabolic markers when elevated at baseline. Hence, vitamin D
should be taken in consideration when planning treatment.
Numerous additional variables govern our interpretation of children studies involving vitamin
D supplementation [2]. Among these factors is the frequency of supplementation. All of the RCTs,
except Kelishadi et al. [30] and Smith et al. [31], employed regular small doses of vitamin D
supplementation. Daily supplementation may have different biological effects [46] in comparison
with intermittent supplementation (monthly, weekly or lesser frequency). Another aspect that could
affect the interpretation of our results are the genetic variants for the causal effect of vitamin D on BP;
this assessment was beyond the scope of our investigation. Ethnicity and genetic differences between
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populations are important determinants in vitamin D metabolism [2]. In a systematic review and
Mendelian randomization analysis using published data, Kunutsor et al. [38] found that particular
genetic variants (vitamin D single nucleotide polymorphisms (SNPs)) had nominally significant
associations with both SBP and DBP. Additional evidence from genetic data coupled with clinical trial
data is needed to identify selected subgroups who could benefit to a greater extent from vitamin D
supplementation [38].
Our analysis has numerous strengths. We followed a systematic approach in our search and
analysis and employed sensitivity analyses to assess the robustness of our results. In general, the risk
of bias of the included studies was low.
However, our analysis had a few limitations. First, the number of identified studies was limited,
with sample sizes smaller than 1000, which might have hindered our ability to detect a statistically
significant effect on BP. Second, we were limited to study-level rather than individual-level data,
which would have been more accurate than the overall mean change. Third, we did not contact
the authors of the three articles where endline SBP and DBP values were not reported [26,29,30],
and accordingly, these articles were not included in the meta-analysis. Fourth, all of the studies,
except Kelishadi et al. [30], have specifically targeted patients who were normotensive at baseline. It is
plausible that normal BP is more likely to remain unchanged with any intervention, including vitamin
D correction. There were some variabilities among the studies, which complicates the comparisons
between included studies and the interpretation of our results, especially in the methods used to
assess 25OHD and BP, doses analyzed, frequency of administration and confounders adjusted for.
Importantly, studies did not adjust for sun exposure, physical activity levels, and socio-economic status,
all of which might modulate the effects of vitamin D interventions [2]. Finally, it was not possible to do
the screening, selection of studies, data extraction, quality assessment and grading of the meta-analysis
in duplicate.
5. Conclusions
In conclusion, the evidence presented in this review and analysis do not support the use of
vitamin D supplementation in clinical practice as a BP-lowering agent in healthy or obese children
and adolescents who are normotensive. Our results remain to be interpreted with caution given the
limited number of included studies, specifically RCTs, as well as their relatively small sample size.
We could not find any study assessing the effect of vitamin D supplementation on participants who
were hypertensive or with cardiometabolic disease. Since the direct effect of vitamin D could be more
potent when subjects have baseline metabolic disturbances, this remains to be explored in future
adequately powered, high-quality RCTs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/4/1163/s1.
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